Global Metabolic Partnering 2014-2020: Deal Trends, Players and Financials - ResearchAndMarkets.com

DUBLIN--()--The "Global Metabolic Partnering 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

This report provides the full collection of Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

  • Trends in Metabolic dealmaking in the biopharma industry since 2014
  • Analysis of Metabolic deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Metabolic deal contract documents
  • Comprehensive access to over 950 Metabolic deal records
  • The leading Metabolic deals by value since 2014
  • Most active Metabolic dealmakers since 2014

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.

The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Metabolic dealmaking trends.

  • Chapter 1 provides an introduction to the report.
  • Chapter 2 provides an overview of the trends in Metabolic dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
  • Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
  • Chapter 4 provides a review of the leading Metabolic deals since 2014. Deals are listed by headline value. The - Chapter includes the top 25 most active Metabolic dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 5 provides comprehensive access to Metabolic deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
  • Chapter 6 provides a comprehensive directory of all Metabolic partnering deals by specific Metabolic target announced since 2014. The - Chapter is organized by specific Metabolic therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Metabolic partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Metabolic technologies and products.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

  • 2XU
  • 3SBio
  • 5LINX
  • 23andMe
  • A*STAR Agency for Science
  • Technology and Research
  • AB-Biotics
  • Abbott Laboratories
  • Abbvie
  • Abby Grace Foundation
  • Abeona Therapeutics
  • Abiogen Pharma
  • Academic Drug Discovery Consortium
  • Academy Medical
  • Acasti Pharma
  • Accord Healthcare
  • Acerus
  • Aceto Corporation
  • Acon Labs
  • Actavis (name changed to Allergan)
  • Activhealth
  • Acurian
  • Admera Health
  • Adocia
  • Advance Pharmaceutical
  • Adverum Biotechnologies
  • Aelan Cell Technologies
  • Aero Pump
  • AEterna Zentaris
  • Aetna
  • Aevi Genomic Medicine
  • Afimmune
  • AgaMatrix
  • AgBiome
  • Agilent Technologies
  • Aguettant
  • Ajinomoto
  • Akero Therapeutics
  • Akers Biosciences
  • AKSA Medical
  • Akston Biosciences
  • Albany Molecular Research
  • Albert Einstein College of Medicine
  • Albion
  • Albumedix
  • Alcon Laboratories
  • Alcresta
  • Alexion Pharmaceuticals
  • ALK-Abello
  • Allegro Ophthalmics
  • Allele Biotechnology and Pharmaceuticals
  • Allergan
  • AllerGenis
  • Alliance Pharma
  • All Star Health Brands
  • Alnylam Pharmaceuticals
  • ALR Technologies
  • Alteogen
  • Alzheimer's Association
  • Amarna Therapeutics
  • Amazentis
  • Ambrosia Nutraceuticals
  • Ambys Medicines
  • A Menarini Diagnostics
  • American Diabetes Association
  • American Gene Technologies
  • American Society for Parenteral and Enteral Nutrition
  • Amgen
  • Amicus Therapeutics
  • Amneal Pharmaceuticals
  • AMRA
  • Amunix
  • Amyris
  • Andromeda Biotech
  • AnGes MG
  • ANI Pharmaceuticals
  • Anji Pharma
  • Anokion
  • Antares Pharma
  • Antaros Medical
  • Antisense Therapeutics
  • AOP Orphan Pharmaceuticals
  • Apollo Endosurgery
  • Apollo Sugar
  • Apricus Biosciences
  • Arcadia Resources
  • ARCH Personalized Medicine Initiative
  • Arcturus Therapeutics
  • Arecor
  • argenx
  • Argon Medical Devices
  • Arix Bioscience
  • Arjuna Naturals
  • Arkray USA
  • Artizan Biosciences
  • Arzeda
  • Ascensia Diabetes Care
  • Ascletis
  • Aspect Biosystems
  • Aspen Holding
  • Astellas Pharma
  • AstraZeneca
  • AstraZeneca HealthCare Foundation
  • Attain Health
  • Atvio Biotech
  • Audentes Therapeutics
  • Australian Department of Health and Ageing
  • Australian Foundation for Diabetes Research
  • AutoGenomics
  • Autotelic
  • Avion Pharmaceuticals
  • Avivagen
  • Avrobio
  • Awamedica
  • AXIM Biotechnologies
  • Axxess Pharma
  • Aytu BioScience
  • Bambino Gesu Children's Hospital
  • Banting & Best Diabetes Centre (BBDC)
  • BASF
  • Baxter International
  • Bayer
  • Baylor College of Medicine
  • Beacon Discovery
  • Becton Dickinson
  • Beijing Sun-Novo Pharmaceutical Research
  • Benchworks
  • Bened Biomedical
  • Bertin Pharma
  • Best Choice
  • Beta-O2
  • Better Living Now
  • Beyond Type 1
  • BGN Technologies
  • BHV Pharmaceuticals
  • Bicycle Therapeutics
  • Bigfoot Biomedical
  • Bina Technologies
  • Bio-Rad Laboratories
  • BIOASTER
  • BioCision
  • Biocodex Microbiota Foundation
  • BIOCORP
  • Biodel
  • Biodelta Nutraceuticals
  • BioGaia
  • Biogen
  • Biohit
  • Bioinn Molecular Diagnosis
  • BiolineRX
  • Biomedical Catalyst Fund (UK)
  • BioMed X Innovation Center
  • BiopharmX
  • and many, many more!

For more information about this report visit https://www.researchandmarkets.com/r/wmwe6k

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900